EBOS Group (EBO) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
19 Jan, 2026Opening remarks and agenda
Chair welcomed attendees in Auckland and online, outlined meeting format, and explained Q&A and voting procedures.
Quorum was declared, directors and executives introduced, and the agenda was set: year highlights, financial review, and formal business with five resolutions.
Chair Elizabeth Coutts and CEO John Cullity presented, followed by business items and meeting conclusion.
Financial performance review
FY 2024 revenue reached $13.2 billion, up 7.8% year-on-year; underlying EBITDA grew 7.3% to $624.3 million.
Net profit after tax rose 7.7% to $303.4 million; EPS increased 6.8% to 157.9 cents.
Healthcare and animal care segments delivered strong organic and acquisition-driven growth.
TerryWhite Chemmart network expanded to 600 stores; animal care EBITDA grew 13.2%.
ROCE aligned with 15% target; cost management improved operating efficiency.
Board and executive committee updates
Board renewal continued: Peter Williams retired, with Mark Bloom and Julie Tay appointed in the last two years.
Matt Muscio elected as director effective January 2025; search for an additional non-executive Australian director ongoing.
Chair signaled intention to retire after succession and knowledge transfer are complete.
Latest events from EBOS Group
- Portfolio transformation and disciplined investment drive sustained EBITDA growth.EBO
Investor Day 2026 - Revenue up 13% and EBITDA up 3.2%, with guidance reaffirmed and strong segment growth.EBO
H1 2026 - FY25 saw strong revenue and EBITDA growth, but EPS fell due to contract loss and margin pressures.EBO
AGM 2025 - Underlying revenue up 12% to $12.3B, EBITDA up 7.5%, FY26 EBITDA guided to $615–635M.EBO
H2 2025 - Record FY24 growth and positive FY25 outlook despite Chemist Warehouse contract ending.EBO
H2 2024 - Underlying EBITDA up 7.1% year-over-year; FY25 guidance and dividend maintained.EBO
H1 2025